Reports Q4 revenue $21.421M, consensus $21.42M. "We are pleased to report a strong finish to the fiscal year, resulting in double-digit sales growth and the successful advancement of our commercial brands. 2022 was a year of progress that we believe has set us on course for a successful new fiscal year," stated Paul Levesque, President and Chief Executive Officer. "As outlined in my letter to shareholders at the start of the new year, we will continue to fully lean into the growing commercial business supported by favorable tailwinds and considerable headroom to grow. We are leveraging our new field force capabilities to expand awareness and utilization of EGRIFTA SV and Trogarzo with specialty prescribers and patients across the continuum of care in HIV and lipodystrophy. We are also actively working towards the identification of potential in-licensing, co-promotion, or immediately accretive product acquisitions in order to accelerate this journey towards positive Adjusted EBITDA. For TH1902, in conjunction with the Scientific Advisory Committee, we are evaluating the necessary changes needed to increase the probability of success in the clinic through stage-gated investment. Additionally, recently released NASH industry data is placing a spotlight on partnering opportunities for our Phase 2b/3 NASH asset, and we remain optimistic about partnership prospects in 2023," concluded Paul Levesque, President and Chief Executive Officer.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on THTX:
- Theratechnologies Reports Financial Results and Business Updates for the Fourth Quarter and Full Year Fiscal 2022
- Theratechnologies Announces Amendment to its Term Loan Facility With Affiliates of Marathon Asset Management
- Theratechnologies Presents New Tesamorelin Data Demonstrating Improvement of Metabolic Syndrome in People with HIV
- Theratechnologies’ tesamorelin may improve metabolic syndrome in HIV patients
- Theratechnologies to amend, optimize protocol for Phase 1 trial of TH1902